Kostnadene ved latent tuberkuloseinfeksjon (LTBI) for det amerikanske helsesystemet

Latent Tuberculosis Infection (LTBI) is a major public health concern in the United States.

Although it is often overshadowed by active tuberculosis (TB) cases, which garner most of the media attention and healthcare resources, LTBI poses a significant challenge to the healthcare system and public health policy. LTBI is characterized by the presence of Mycobacterium tuberculosis in an individual’s body without clinical manifestations of active disease. Though asymptomatic, this condition can eventually progress into active tuberculosis if left untreated. The broader implications of LTBI in terms of cost to the U.S. healthcare system are complex, multifaceted, and evoke critical discussions on prevention, treatment, and public health strategies.

Understanding LTBI and Its Epidemiology

To appreciate the financial burdens associated with LTBI, it is vital to first understand its epidemiology. According to the Sentre for sykdomskontroll og forebygging (CDC), an estimated 13 million people in the U.S. are living with LTBI. The risk factors for LTBI include recent immigration from high-burden countries, compromised immune systems, and close contact with individuals who are actively infected. In addition to being a public health issue, the economic impact of managing LTBI cannot be understated.

Direct Healthcare Costs

The direct healthcare costs associated with LTBI include screening, diagnosis, and treatment. In the U.S., the two main tests used to detect LTBI are the tuberculin skin test (TST) and interferon-gamma release assays (IGRAs). These tests can cost between $20 to $100 per patient. Adding follow-up consultations, chest X-rays, and additional diagnostic testing, the total baseline cost for initial LTBI assessment can quickly escalate into several hundred dollars per individual.

Once diagnosed, the treatment for LTBI typically involves a regimen of isoniazid or rifapentine for a duration of six to nine months. The cost of these medications can range from $500 to $1,000 per course, depending on various factors such as insurance coverage, pharmacy choice, and patient adherence to the prescribed regimen. In the context of the large number of individuals with LTBI, these costs aggregate significantly, burdening both the healthcare system and individual patients.

Indirect Costs

Beyond the direct healthcare expenditures, there are substantial indirect costs associated with LTBI. These include lost productivity due to illness, costs associated with patients requiring time off work to attend medical appointments, and potentially, the societal costs of treating health complications arising from untreated LTBI. The estimated economic burden due to lost productivity due to TB diseases alone amounts to billions of dollars annually.

Furthermore, there are the costs associated with contact tracing and preventative programs aimed at controlling the spread of TB. Public health departments actively engage in notifying individuals who may have been exposed to active TB cases. This process involves epidemiological investigations, screening, and follow-up, all of which require significant allocation of resources.

Public Health Implications

The public health implications of LTBI extend beyond the individual to community health, economic stability, and overall public safety. The CDC emphasizes the importance of addressing LTBI not only to prevent the progression to active TB but also to reduce the risk of outbreaks. The costs associated with a TB outbreak can be astronomical, as seen in multiple states over the past decade. Managing an outbreak necessitates extensive public health interventions, including isolating infected individuals, mass screenings, and heightened healthcare provider education.

Socioeconomic Factors and Disparities

It is also crucial to factor in the socioeconomic disparities that influence both LTBI prevalence and treatment adherence. Communities with lower socioeconomic status often have higher rates of LTBI due to inadequate healthcare access, poor living conditions, and crowded housing. This situation exacerbates the burden on the healthcare system, as these communities may struggle to participate in proactive screening or follow-up treatment.

Efforts to address health inequities must be included in discussions about the cost of LTBI. Investment in community health initiatives, including outreach programs and culturally competent healthcare services, will be required to reduce LTBI rates in at-risk communities. Though requiring upfront financial resources, these investments can reduce long-term costs associated with treating active TB cases and lost productivity.

Konklusjon

The cost of Latent Tuberculosis Infection to the U.S. healthcare system is significant, encompassing direct and indirect expenses, public health implications, and exacerbated health disparities. As the country continues to navigate the complexities of tuberculosis management, including the challenges posed by drug-resistant strains and the COVID-19 pandemic, it will be critical to reassess priorities and allocate appropriate resources towards LTBI prevention and treatment. Strategic investments in public health initiatives could ultimately lessen the burden of LTBI, not only benefiting individual patients but also enhancing community resilience and national health security long-term. By recognizing and acting upon the multifaceted costs and implications of LTBI, the U.S. can prioritize a more effective and equitable public health framework that encourages complete, sustainable TB control.